Eisai Receives Marketing Authorization Approval for Aricept Evess (donepezil hydrochloride), Orodispersible Tablet in the U.K.
Eisai Co., Ltd. (Headquarters: Tokyo, President: Haruo Naito) announced that its U.K. subsidiary, Eisai Ltd. (Headquarters: London, Managing Director: Paul Hooper), has received marketing authorization approval from the Medicines and Healthcare products Regulatory Agency (MHRA) on May 17 for orodispersible tablets, Aricept Evess 5mg and Aricept Evess 10mg. The MHRA will act as the Reference Member State for the European Union's (EU) Mutual Recognition procedure.
Aricept Evess is designed to make administration easier for Alzheimer's disease patients who have difficulty swallowing tablets. The company has already started marketing an orodispersible tablet of Aricept in Japan since July 2004. In the U.S., Eisai received approval for orodispersible tablets in October 2004.
Aricept, an acetylcholinesterase inhibitor developed by Eisai Co., Ltd. in Japan, increases the concentration of acetylcholine, a neurotransmitter in the brain. Aricept is currently indicated for the treatment of mild to moderate Alzheimer's disease and is marketed in 76 countries worldwide.
Eisai Co., Ltd.
Corporate Communications Department
Phone 03-3817-5120 (Tokyo)